Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

Abstract The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion in vitro and reduces their metastatic potential in intrasplenic tumour mou...

ver descrição completa

Detalhes bibliográficos
Principais autores: Maya Jeitany, Cédric Leroy, Priscillia Tosti, Marie Lafitte, Jordy Le Guet, Valérie Simon, Debora Bonenfant, Bruno Robert, Fanny Grillet, Caroline Mollevi, Safia El Messaoudi, Amaëlle Otandault, Lucile Canterel‐Thouennon, Muriel Busson, Alain R Thierry, Pierre Martineau, Julie Pannequin, Serge Roche, Audrey Sirvent
Formato: Artigo
Idioma:English
Publicado em: Springer Nature 2018-02-01
coleção:EMBO Molecular Medicine
Assuntos:
collagen receptor
colorectal cancer
invasion
targeted therapy
tyrosine kinase
Acesso em linha:https://doi.org/10.15252/emmm.201707918

Internet

https://doi.org/10.15252/emmm.201707918

Registros relacionados